InvestSMART

Burgundy Diamond Mines Limited (ASX: BDM) - Announcements

- Current share price for BDM : $0.017

ASX company news and announcements for Burgundy Diamond Mines Limited (BDM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Burgundy Diamond Mines Limited (BDM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Burgundy Diamond Mines Limited (BDM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Burgundy Diamond Mines Limited (BDM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$24 New Japanese protozoal patent for BDM-I 22 May 2013 10:29AM $0.027 $0.017 fallen by 37.04%
$24 BDM-I progress in NIH Research Program as Fungal Infection T 10 May 2013 9:56AM $0.032 $0.017 fallen by 46.88%
$24 Appendix 4C - quarterly 30 Apr 2013 10:30AM $0.033 $0.017 fallen by 48.48%
$24 Additional Antimicrobial Patent Granted in China 21 Feb 2013 11:05AM $0.038 $0.017 fallen by 55.26%
$24 Half Yearly Report and Accounts 21 Feb 2013 9:53AM $0.038 $0.017 fallen by 55.26%
$24 BioDIem extends co-operative agreement with USAMRIID 14 Feb 2013 10:39AM $0.040 $0.017 fallen by 57.50%
$24 Progress to POC testing of BDM-I effect against parasites 8 Feb 2013 2:20PM $0.040 $0.017 fallen by 57.50%
$24 Appendix 4C - quarterly 31 Jan 2013 4:06PM $0.044 $0.017 fallen by 61.36%
$24 SII progresses international plans for BioDiem vaccines 12 Dec 2012 9:39AM $0.051 $0.017 fallen by 66.67%
$24 Japanese Patent Office to grant new patent for antimicrobial 21 Nov 2012 12:22PM $0.040 $0.017 fallen by 57.50%
$24 Broad spectrum antimicrobial partnership with Griffith Uni 8 Nov 2012 10:27AM $0.047 $0.017 fallen by 63.83%
$24 BioDiem Replacement Prospectus 1 Nov 2012 4:51PM $0.048 $0.017 fallen by 64.58%
$24 Appendix 4C - quarterly 24 Oct 2012 2:59PM $0.048 $0.017 fallen by 64.58%
$24 Extension to Closing date for Renounceable Rights Issue 24 Oct 2012 2:58PM $0.048 $0.017 fallen by 64.58%
$24 BDM Reports further progress for BDM-I anti-microbial 18 Oct 2012 10:01AM $0.045 $0.017 fallen by 62.22%
$24 Renounceable Issue 1 Oct 2012 10:20AM $0.062 $0.017 fallen by 72.58%
$24 Reinstatement to Official Quotation 28 Sep 2012 10:19AM $0.062 $0.017 fallen by 72.58%
$24 BioDiem Renounceable Rights Issue 28 Sep 2012 10:19AM $0.062 $0.017 fallen by 72.58%
$24 Suspension from Official Quotation 27 Sep 2012 9:55AM $0.062 $0.017 fallen by 72.58%
$24 Trading Halt 25 Sep 2012 11:42AM $0.062 $0.017 fallen by 72.58%
$24 Preliminary Final Report 31 Aug 2012 1:24PM $0.055 $0.017 fallen by 69.09%
$24 Successful growth of BDM's Virus in VIVALIS EB66 Cell Line 21 Aug 2012 9:48AM $0.065 $0.017 fallen by 73.85%
$24 BioDiem granted European patent for BDM-I antimicrobial 8 Aug 2012 10:30AM $0.060 $0.017 fallen by 71.67%
$24 Appendix 4C - quarterly 27 Jul 2012 3:08PM $0.055 $0.017 fallen by 69.09%
$24 BDM presents findings at international eye research meeting 23 Jul 2012 9:56AM $0.061 $0.017 fallen by 72.13%

326 - 350 of 458 results

Page 14 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.